nodes	percent_of_prediction	percent_of_DWPC	metapath
Ipratropium bromide—Chest pain—Teniposide—lymphatic system cancer	0.005	0.005	CcSEcCtD
Ipratropium bromide—Urinary retention—Vincristine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Ipratropium bromide—Lung disorder—Methotrexate—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Ipratropium bromide—Oedema—Teniposide—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Ipratropium bromide—Infection—Teniposide—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Ipratropium bromide—Dysphagia—Carmustine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Ipratropium bromide—Stomatitis—Bleomycin—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Ipratropium bromide—Tachycardia—Teniposide—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Ipratropium bromide—Pruritus—Mechlorethamine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ipratropium bromide—Cough—Fludarabine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Ipratropium bromide—Hypotension—Teniposide—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Ipratropium bromide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Ipratropium bromide—Myalgia—Fludarabine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Ipratropium bromide—Haemoglobin—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Ipratropium bromide—Haemorrhage—Bleomycin—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Ipratropium bromide—Dyspnoea—Teniposide—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Ipratropium bromide—Dysuria—Vincristine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Ipratropium bromide—Oedema—Fludarabine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Ipratropium bromide—Infection—Fludarabine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Ipratropium bromide—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Ipratropium bromide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Ipratropium bromide—Stomatitis—Carmustine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Ipratropium bromide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Ipratropium bromide—Rash—Mechlorethamine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Ipratropium bromide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Ipratropium bromide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Ipratropium bromide—Flushing—Bleomycin—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Ipratropium bromide—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Ipratropium bromide—Stomatitis—Vincristine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Ipratropium bromide—Sweating—Vincristine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Ipratropium bromide—Nausea—Mechlorethamine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Ipratropium bromide—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Ipratropium bromide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Ipratropium bromide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Ipratropium bromide—Haemoglobin—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Ipratropium bromide—Urticaria—Teniposide—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Ipratropium bromide—Haemorrhage—Carmustine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Ipratropium bromide—Abdominal pain—Teniposide—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Ipratropium bromide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Ipratropium bromide—Sweating—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Ipratropium bromide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Ipratropium bromide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Ipratropium bromide—Ulcer—Methotrexate—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Ipratropium bromide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Ipratropium bromide—Visual impairment—Carmustine—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Ipratropium bromide—Fatigue—Fludarabine—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Ipratropium bromide—Inflammation—Methotrexate—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Ipratropium bromide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Ipratropium bromide—Pain—Fludarabine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Ipratropium bromide—Constipation—Fludarabine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Ipratropium bromide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Ipratropium bromide—Urethral disorder—Vincristine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Ipratropium bromide—Eye disorder—Carmustine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Ipratropium bromide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Ipratropium bromide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Ipratropium bromide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Ipratropium bromide—Flushing—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Ipratropium bromide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Ipratropium bromide—Asthenia—Teniposide—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Ipratropium bromide—Pruritus—Teniposide—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Ipratropium bromide—Cough—Bleomycin—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Ipratropium bromide—Diarrhoea—Teniposide—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Ipratropium bromide—Myalgia—Bleomycin—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Ipratropium bromide—Chest pain—Bleomycin—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Ipratropium bromide—Back pain—Carmustine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Ipratropium bromide—Vision blurred—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Ipratropium bromide—Tremor—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Ipratropium bromide—Oedema—Bleomycin—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Ipratropium bromide—Infection—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Ipratropium bromide—Back pain—Vincristine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Ipratropium bromide—Vomiting—Teniposide—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Ipratropium bromide—Asthenia—Fludarabine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Ipratropium bromide—Rash—Teniposide—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Ipratropium bromide—Dermatitis—Teniposide—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Ipratropium bromide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Ipratropium bromide—Headache—Teniposide—lymphatic system cancer	0.003	0.003	CcSEcCtD
Ipratropium bromide—Pruritus—Fludarabine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Ipratropium bromide—Back pain—Mitoxantrone—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Ipratropium bromide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Ipratropium bromide—Hypotension—Bleomycin—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Ipratropium bromide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Ipratropium bromide—Hypertension—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Ipratropium bromide—Nausea—Teniposide—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Ipratropium bromide—Chest pain—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Ipratropium bromide—Myalgia—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Ipratropium bromide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Ipratropium bromide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Ipratropium bromide—Hypertension—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Ipratropium bromide—Oedema—Carmustine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Ipratropium bromide—Myalgia—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Ipratropium bromide—Cough—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ipratropium bromide—Infection—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ipratropium bromide—Vomiting—Fludarabine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ipratropium bromide—Rash—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Ipratropium bromide—Dermatitis—Fludarabine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Ipratropium bromide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Ipratropium bromide—Pain—Bleomycin—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Ipratropium bromide—Headache—Fludarabine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Ipratropium bromide—Tachycardia—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Ipratropium bromide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Ipratropium bromide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Ipratropium bromide—Oedema—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Ipratropium bromide—Infection—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Ipratropium bromide—Hypotension—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Ipratropium bromide—Oedema—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Ipratropium bromide—Nausea—Fludarabine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Ipratropium bromide—Infection—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Ipratropium bromide—Urticaria—Bleomycin—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Ipratropium bromide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Ipratropium bromide—Insomnia—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Ipratropium bromide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Ipratropium bromide—Paraesthesia—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Ipratropium bromide—Hypotension—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Ipratropium bromide—Dyspnoea—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Ipratropium bromide—Somnolence—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Ipratropium bromide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ipratropium bromide—Insomnia—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Ipratropium bromide—Paraesthesia—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ipratropium bromide—Constipation—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ipratropium bromide—Pain—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Ipratropium bromide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Ipratropium bromide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Ipratropium bromide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ipratropium bromide—Fatigue—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ipratropium bromide—Asthenia—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ipratropium bromide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Ipratropium bromide—Constipation—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ipratropium bromide—Pain—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ipratropium bromide—Asthma—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ipratropium bromide—Pruritus—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Ipratropium bromide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Ipratropium bromide—Constipation—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ipratropium bromide—Pain—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ipratropium bromide—Abdominal pain—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Ipratropium bromide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Ipratropium bromide—Dysuria—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Ipratropium bromide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Ipratropium bromide—Abdominal pain—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Ipratropium bromide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Ipratropium bromide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Ipratropium bromide—Vomiting—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ipratropium bromide—Rash—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ipratropium bromide—Dermatitis—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ipratropium bromide—Asthenia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Ipratropium bromide—Stomatitis—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Ipratropium bromide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Vincristine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Ipratropium bromide—Sweating—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Ipratropium bromide—Epistaxis—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ipratropium bromide—Asthenia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ipratropium bromide—Diarrhoea—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ipratropium bromide—Nausea—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ipratropium bromide—Asthenia—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Ipratropium bromide—Dizziness—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Ipratropium bromide—Haemoglobin—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Ipratropium bromide—Diarrhoea—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ipratropium bromide—Haemorrhage—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ipratropium bromide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Ipratropium bromide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ipratropium bromide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ipratropium bromide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ipratropium bromide—Vomiting—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Ipratropium bromide—Dizziness—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ipratropium bromide—Rash—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ipratropium bromide—Dermatitis—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ipratropium bromide—Visual impairment—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Ipratropium bromide—Headache—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Ipratropium bromide—Eye disorder—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ipratropium bromide—Tinnitus—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ipratropium bromide—Vomiting—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ipratropium bromide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Ipratropium bromide—Rash—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Ipratropium bromide—Dermatitis—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Ipratropium bromide—Headache—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ipratropium bromide—Nausea—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Ipratropium bromide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ipratropium bromide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ipratropium bromide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ipratropium bromide—Rash—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ipratropium bromide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ipratropium bromide—Headache—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ipratropium bromide—Nausea—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Ipratropium bromide—Dysgeusia—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ipratropium bromide—Nausea—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Ipratropium bromide—Back pain—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ipratropium bromide—Vision blurred—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ipratropium bromide—Cough—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ipratropium bromide—Chest pain—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Ipratropium bromide—Myalgia—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Ipratropium bromide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ipratropium bromide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Ipratropium bromide—Infection—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ipratropium bromide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ipratropium bromide—Skin disorder—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ipratropium bromide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ipratropium bromide—Hypotension—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Ipratropium bromide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ipratropium bromide—Insomnia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ipratropium bromide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ipratropium bromide—Dyspnoea—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ipratropium bromide—Somnolence—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ipratropium bromide—Dyspepsia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ipratropium bromide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ipratropium bromide—Fatigue—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ipratropium bromide—Pain—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ipratropium bromide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ipratropium bromide—Urticaria—Methotrexate—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Ipratropium bromide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000988	0.000988	CcSEcCtD
Ipratropium bromide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Ipratropium bromide—Asthenia—Methotrexate—lymphatic system cancer	0.000896	0.000896	CcSEcCtD
Ipratropium bromide—Pruritus—Methotrexate—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Ipratropium bromide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Ipratropium bromide—Dizziness—Methotrexate—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Ipratropium bromide—Vomiting—Methotrexate—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Ipratropium bromide—Rash—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Ipratropium bromide—Dermatitis—Methotrexate—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Ipratropium bromide—Headache—Methotrexate—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Ipratropium bromide—Nausea—Methotrexate—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
